Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

853 Features
Swine Flu Update: 02/11/2009

02 Nov 09

Weekly Swine Flu Update for the Week Ending November 1st.
Max Golby

IMPORTANT DECISIONS FOR PHARMA IN INDIA

16 Oct 09

In this edition of StrategicEdge, CBR Pharma Insights discusses some of the recent rulings by the Indian courts and their impact on the pharmaceutical industry's increasing interest in India.
CBR Pharma Insights

H1N1 Vaccine: It’s Arrived

13 Oct 09

Ever since the H1N1 virus first came onto the world map in April, ‘Where’s the vaccine?’ has been the cardinal question on everybody’s lips. As world governments scrambled to control the outbreak, supranational bodies such as the World Health Organization (WHO) threw themselves at the task of producing weekly updates for a virus which we originally knew very little about.
Max Golby

Swine Flu Update: 02/10/2009

01 Oct 09

Weekly Swine Flu Update for the Week Ending October 2nd.
Max Golby

HIV Vaccine: With New Hope Comes The Potential Dangers of Complacency

30 Sep 09

It is frightening because no one knows what's causing it, said a 28-year old law student who went to the St. Mark's Clinic in Greenwich Village last week complaining of swollen glands, thought to be one early symptom of the disease. Every week a new theory comes out about how you're going to spread it. - The New York Times , August 8th 1982.
Max Golby

ECCO-ESMO: Erbitux combined with FOLFIRI or FOLFOX4 significantly extends overall survival in advanced bowel cancer

28 Sep 09

A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen

What does the multi-channel enabled pharma’ company look like?

17 Sep 09

Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners

What Employers Really Want

16 Sep 09

In the eyes of many graduates, the economic recession has brought a new-found negativity to the job market. Thankfully, the climate is probably less dire than the situation sometimes imagined.
Max Golby

Can Schering-Plough’s asenapine improve prospects for schizophrenia and bipolar patients

16 Sep 09

More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen

Swine Flu Update: 10/09/2009

14 Sep 09

Weekly Swine Flu Update for the Week Ending September 10th
Max Golby

Swine Flu Update: 04/09/2009

04 Sep 09

Weekly Swine Flu Update for the Week Ending September 4th.
Max Golby

The Future of e-Detailing: 2009 and Beyond

03 Sep 09

Max Golby, Freelance Journalist, takes a look at the history of the e-Detailing market, considers what the e-Detail of the future might look like and asks what marketing departments can learn from an academic analysis of the instrument.
Max Golby

Swine Flu Update: 28/08/2009

28 Aug 09

Weekly Swine Flu Update for the Week Ending August 27th.
Max Golby

Swine Flu Update: 21/08/2009

21 Aug 09

Weekly Swine Flu Update for the Week Ending August 16th.
Max Golby

U.S. Healthcare Reform: 1993 Re-Visited

11 Aug 09

As Capitol Hill readies itself for the August Recess, and as President Barack Obama demands that a bill reach his desk in the Oval Office by October, healthcare reform still finds itself in more-or-less the same quagmire as it did in 1993. We take a look at the chances of comprehensive reform this year and tackle the nitty-gritty of one of the most complex and polarising issues of Washington politics today.
Max Golby

Weekly Swine Flu Update

30 Jul 09

Weekly Swine Flu Update for the Week Ending July 26.
Max Golby

Career Focus: Medical Communications

29 Jul 09

The field of Medical Communications offers a whole host of opportunities for new science graduates - both in medical publishing and pharma.
Max Golby

NHS finances: All Bets Are Off

28 Jul 09

Ahead of the NHS Confederation Conference last month, David Nicholson, Chief Executive of NHS pulled no punches with his assessment of NHS finances.
Miriam George

ABPI Medical Representatives Exam bookings

27 Jul 09

ABPI have developed an on-line exam bookings website to facilitate the process of booking the ABPI Medical Representatives Exam.
ABPI

The Wireless GP

22 Jul 09

Generational stereotypes are never easy to swallow, but when it comes to doctors and an investment in social media, the new generations of medical professionals are increasingly going online for both professional collaboration and patient support.
Max Golby

Drug repositioning strategies: a different approach to innovation

15 Jul 09

With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.
Priyanka Adhikari

World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios

01 Jul 09

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.
Priyanka Adhikari

Quick Look: Alternative Therapies

16 Jun 09

Quick Look article from Max Golby about Alternative Therapies
Max Golby

Pharmaceutical Curriculum Vitae, Works of Art or Dissertations?

15 Jun 09

Unless it paints the right picture you’re letting the side down!

In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many more from agencies who ‘piggy back’ in. So now, more than ever, your CV needs to stand out and be tailored to the role and client and submitted by an agency with valid access.
Avril Horn PhD

ASCO meeting 2009: current blockbusters advance standard care in new indications

12 Jun 09

Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.
Datamonitor

Serono’s Erbitux set to be first biologic treatment for mCRC in the UK

11 Jun 09

Dr Wolfgang Wein, Executive Vice-President of Merck Serono’s Oncology Business comments on the recent final appraisal determination by NICE paving the way for its leading oncology product Erbitux to benefit UK mCRC patients.
Olwen Glynn Owen - Pharmiweb Field reporter

The pharmaceutical industry faces unprecedented barriers to evolution

05 Jun 09

Despite the pharmaceutical industry's evolving business model in response to growing regulatory constraints, the sector is facing unprecedented challenges caused by the economic downturn and President Obama's planned overhaul of the US healthcare system. To continue on its journey towards 'Pharma 2.0', the industry must balance the more pressing short term issues against longer term trends
Priyanka Adhikari - Datamonitor

Quick Look: Swine Flu

03 Jun 09

Quick Look article written by Max Golby, focusing on topic of swine flu.
Max Golby

Impact of the credit crunch: how will the NHS respond to its two year window of opportunity?

20 May 09

Senior Department of Health executives, speaking at a recent NHS Alliance Conference, suggested that the NHS has two years left before it starts to the credit crunch’s bite – maybe less if there is an election in a years’ time. But this should not be cause complacency in the health sector. The message is, invest wisely now so that you are well prepared for the fallow times ahead.
PDC Healthcare

Advertising